Polyclonal versus monoclonal rejection prophylaxis after heart transplantation: a randomised study

  • A. H. M. M. Balk
  • K. Meeter
  • M. L. Simoons
  • R. M. L. Brouwer
  • P. E. Zondervan
  • B. Mochtar
  • E. Bos
  • W. Weimar
Conference paper

Abstract

Recent studies comparing the effects of induction therapy with polyclonal antilymphocyte globulins (ALG) or with monoclonal T-cell-specific antibodies are not unanimous. Therefore, 55 heart recipients were allocated to either 7-day courses of polyclonal ALG (n = 28) or of monoclonal OKT3 (n = 27). Additionally, azathioprine and low dose steroids were given. There were no severe side effects after OKT3; the course of ALG, however, had to be discontinued in 20 patients because of extensive flares. No differences between the two groups were found in freedom from rejection or in the incidence of infection. The 1- and 2-year survival was 96% in both groups. Although monoclonal and polyclonal induction therapies are equally effective for rejection prophylaxis, OKT3 may be preferred because of a lack of important side effects. However, the fact that a shorter course of ALG is equally effective may be in favour of ALG.

Key words

Heart transplantation Rejection prophylaxis Polyclonal/monoclonal antibodies 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Andreone PA, Olviari MT, Elick B, Arentzen CE, Sibley RK, Bolman RM, Simmons RL, Ring WS (1986) Reduction of infectious complications following heart transplantation with triple-drug immunotherapy. J Heart Transplant 5:13–19PubMedGoogle Scholar
  2. 2.
    Balk AH, Simoons ML, Jutte NH, Brouer ML, Meeter K, Mochtar B, Weimar W (1990) Sequential OKT3 and cyclosporin after heart transplantation: a randomized study with single and cyclic OKT3. Clin Transplant 5:301–305Google Scholar
  3. 3.
    Billingham ME (1981) Diagnosis of cardiac rejection by endomyocardial biopsy. Heart Transplant 1:25Google Scholar
  4. 4.
    Breisblatt WM, Schulman DS, Stein K, Wolfe CJ, Whiteside T, Kormos R, Hardesty RL (1991) Hemodynamic response to OKT3 in orthotopic heart transplant recipients: evidence for reversible myocardial dysfunction. J Heart Lung Transplant 10: 359–365PubMedGoogle Scholar
  5. 5.
    Bristow MR, Renlund DG, Gilbert E, Lee HR, Gay WA, O’Connell JB (1988) Murine monoclonal CD-3 antibody in cardiac transplantation: anti-rejection treatment and preliminary results in a prospectively randomized trial for prophylaxis. Clin Transplant 2:163–168Google Scholar
  6. 6.
    Brouwer RML, Balk AHMM, Weimar W (1991) OKT3 and the incidence of lymphoproliferative disorders after cardiac transplantation. N Engl J Med 324:1437CrossRefGoogle Scholar
  7. 7.
    Constanzo-Nordin MR, Silver MA, O’Connell JB, Pifarre R, Grady KL, Winter GI, Murdock DK, Sullivan HJ, Grieco JG, Scanlon PJ, Robinson J A (1987) Successful reversal of acute cardiac allograft rejection with OKT3 monoclonal antibody. Circulation 76 [Suppl V]: V 71-V 80Google Scholar
  8. 8.
    Cosimi AB (1987) OKT3: first dose safety and success. Nephron 46 [Suppl I]: 12–18PubMedCrossRefGoogle Scholar
  9. 9.
    Frist WH, Merril WH, Eastburn TE, Atkinson JB, Stewart JR, Hammon JW, Bender HW (1990) Unique antithymocyte serum versus OKT3 for induction immunotherapy after heart transplantation. J Heart Transplant 9:489–494PubMedGoogle Scholar
  10. 10.
    Gilbert EM, Dewitt ChM, Eiswirth CC, Renlund DG, Menlove RL, Freedman LA, Herrick CM, Gay WA, Bristow MR (1987) Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am J Med 82:202PubMedCrossRefGoogle Scholar
  11. 11.
    Gilbert E, Eiswirth CC, Renlund DG, Menlove RL, Dewitt CM, Freedman LA (1987) Use of orthoclone OKT3 monoclonal antibody in cardiac transplantation: early experience with rejection prophylaxis and treatment of refractory rejection. Transplant Proc 19:45–53PubMedGoogle Scholar
  12. 12.
    Hegewald MG, O’Connell JB, Renlund DG, Lee HR, Burton NA, Karwande SV, Jones KW, Lassetter JE, Bristow MR (1989) OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation. J Heart Transplant 8:303–310PubMedGoogle Scholar
  13. 13.
    Kirklin JK, Bourge RC, White-Williams C, Naftel DC, Thomas FT, Thomas JM, Phillips MG (1990) Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3. J Thorac Cardiovasc Surg 99: 716–724PubMedGoogle Scholar
  14. 14.
    Menkis AH, Powell AM, Novick RJ, McKenzie FN, Kostuk WJ, Pflugfelder PW, Brown J, Rochon J, Chan I, Stiller C (1991) Prospective randomized trial of short term immunosuppressive prophylaxis using OKT3 or Minnesota equine ALG (abstr). J Heart Lung Transplant 10:163Google Scholar
  15. 15.
    Metselaar HJ, Balk AHMM, Mochtar B, Rothbarth PH, Weimar W (1990) Prophylactic use of anti-CMV immunoglobuline in CMV seronegative heart transplant recipients. Chest 97: 396–399PubMedCrossRefGoogle Scholar
  16. 16.
    Miller RA, Maloney DG, McKillop J, Levey R (1981) In-vivo effects of murine hybridoma monoclonal antibody in a patient with T cell leukemia. Blood 58:78–86PubMedGoogle Scholar
  17. 17.
    Mundy J, Chang V, Keogh A, MacDonald P, Spratt P (1991) Prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation: increased morbidity with OKT3 (abstr). J Heart Lung Transplant 10:163Google Scholar
  18. 18.
    Orthomulticenter Transplant Study Group (1985) A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313:337–342CrossRefGoogle Scholar
  19. 19.
    Starnes V, Oyer P, Stinson E, Dein J, Shumway N (1989) Prophylactic OKT3 used as induction therapy for heart transplantation. Circulation 80 [Suppl III]: 79–83Google Scholar
  20. 20.
    Stein KI, Landowski J, Kormos R, Armitage J (1989) The cardiopulmonary response to OKT3 in orthotopic cardiac transplant recipients. Chest 95:817–821PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • A. H. M. M. Balk
    • 1
  • K. Meeter
    • 1
  • M. L. Simoons
    • 1
  • R. M. L. Brouwer
    • 1
  • P. E. Zondervan
    • 1
  • B. Mochtar
    • 1
  • E. Bos
    • 1
  • W. Weimar
    • 1
  1. 1.Thoraxcenter and Department of Internal Medicine IUniversity Hospital Rotterdam - DijkzigtRotterdamThe Netherlands

Personalised recommendations